NRP1 and melanoma: First, the knock-down of either Gal-1 or NRP1 showed the same functional impact on restoring drug sensitivity in melanoma cells; moreover, the effects of these treatments were not additive and were instead mutually exclusive, suggesting that the targeted effectors lie in the same signaling pathway.